



NDA 20-636/S-016

NDA 20-933/S-006

Boehringer Ingelheim Pharmaceuticals, Inc.
Attention: Mr. Kevin Dransfield
Associate Director, Regulatory Affairs
900 Ridgebury Rd./P.O. Box 368
Ridgefield, CT 06877-0368

Dear Mr. Dransfield:

Please refer to your supplemental new drug application(s) dated March 20, 2001, received March 22, 2001, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for VIRAMUNE[®] (nevirapine) Tablets and VIRAMUNE[®] (nevirapine) Suspension.

We acknowledge receipt of your submissions dated August 24, 2001, November 16, 2002, December 2, 2002, and December 20, 2002.

These supplemental new drug applications provide for the inclusion of information in the VIRAMUNE[®] (nevirapine) labels regarding renal and hepatic insufficiency.

We have completed the review of these applications, as amended, and have concluded that adequate information has been presented to demonstrate that the drug products are safe and effective for use as recommended in the agreed upon labeling text. Accordingly, these applications are approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert, text for the patient package insert, Medication Guide, immediate container and carton labels) and/or submitted labeling (package insert submitted December 3, 2002, patient package insert submitted December 3, 2002, Medication Guide submitted December 3, 2002, immediate container and carton labels submitted December 3, 2002). Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, these submissions should be designated "FPL for approved supplement NDA 20-636/S-016, NDA 20-933/S-006." Approval of these submissions by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

NDA 20-636

NDA 20-933

Page 2

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Destry Sullivan, Regulatory Project Manager, at (301) 827. 2335.

Sincerely,

{See appended electronic signature page}

Debra Birnkrant, M.D.
Director
Division of Antiviral Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Debra Birnkrant
12/31/02 02:27:37 PM
NDA 20-933, 20-636